BTC Health’s wholly owned investee company, BTC Pharma, has amended its existing license and distribution agreement for the Bronchitol and Aridol products.
It has also extended its partnership with Arna Pharma, with effect from 1 February 2025.
Under the terms of the amendment, BTC Pharma has assigned Singapore and Malaysia distribution rights to the products to Arna Pharma. Arna Pharma will pay BTC Pharma a single-digit royalty on sales in these markets for the first three years and has granted BTC Pharma an indefinite license to the products for the Australian and New Zealand markets.
Arna Pharma says it’s building a pipeline of novel pharmaceutical products. It has granted BTC Pharma the first right of refusal to commercialise its specialty products in the Australian and NZ markets.
Commenting on the partnership, BTC Health Executive Chairman Dr Richard Treagus says: “This expanded partnership agreement with Arna Pharma combines the established strengths of Arna Pharma’s product development and manufacturing capabilities and BTC Pharma’s distribution and marketing expertise. We are very excited by the potential of bringing novel pharmaceutical products to Australian patients.”
Arna Pharma Managing Director Hemant Gulhane adds: “We are delighted to strengthen our partnership with BTC Pharma, extending our collaboration to new markets.
“This agreement reflects our shared commitment to delivering innovative respiratory solutions to patients in Singapore and Malaysia.
“With an indefinite license for Bronchitol and Aridol, we are positioned for long-term success.
“Additionally, BTC Pharma’s first right of refusal for our new product pipeline underscores the trust in Arna Pharma’s innovation. We look forward to expanding access to high-quality treatments and achieving new milestones together.”
